Database to predict pancreatic cancer from IPMN
Intraductal Papillary Mucinous Neoplasm (IPMN) Database - A Tool to Predict Pancreatic Cancer
This study is trying to build a database to help understand how a specific type of pancreatic growth called IPMN can turn into pancreatic cancer, so we can improve early detection and treatment for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | St Vincent's Hospital Melbourne Academic / other |
| Locations | 1 site (Fitzroy, Victoria) |
| Trial ID | NCT05117723 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a comprehensive database to track the progression of Intraductal Papillary Mucinous Neoplasm (IPMN) to pancreatic cancer. It will utilize surgical pathology, radiology, and biochemical diagnosis to delineate the disease's progression. The study also seeks to outline management strategies for patients with IPMN, validate existing consensus guidelines, and identify potential risk factors associated with the progression to malignancy. By gathering and analyzing this data, the study hopes to improve early detection and treatment strategies for pancreatic cancer.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients aged 18 to 90 who have been diagnosed with a cystic mass consistent with IPMN.
Not a fit: Patients who decline to participate in the study will not receive any benefit from its findings.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and management of pancreatic cancer, potentially saving lives.
How similar studies have performed: Other studies have shown success in utilizing databases to track disease progression and improve management strategies, making this approach promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients between the age of 18 and 90 years old who have been identified with a cystic mass consistent with IPMN on imaging Exclusion Criteria: * Patients who formally decline enrolment into the study
Where this trial is running
Fitzroy, Victoria
- St Vincent's Hospital Melbourne — Fitzroy, Victoria, Australia (Recruiting)
Study contacts
- Principal investigator: Adrian Fox — St Vincent's Hospital Melbourne
- Study coordinator: Lynn Chong
- Email: lynn.chong@svha.org.au
- Phone: +61 3 9231 2074
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.